TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 22441580
Drug: Conservative treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conservative treatment for normal compliance (CON-NC)
Study: 22441580
Drug: Conservative treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conservative treatment for low compliance (CON-LC)
Study: 17362728
Drug: Belzer solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Belzer solution
Study: 8884833
Drug: Custodiol solution
Normalized name: CUSTODIOL HTK SOLN
Approvals — FDA: no, EMA: no, PMDA: no
Description: Custodiol solution
Study: 12271807
Drug: Cognitive-behavioural therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive-behavioural therapy (CBT) plus routine care
Study: 8789468
Drug: Heparin-coated circuits
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heparin-coated circuits (COMB-HC)
Study: 8789468
Drug: Heparin-coated circuits
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heparin-coated circuits (CABG-HC)
Study: 1498296
Drug: Diltiazem (0.15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diltiazem (0.15 mg/kg bolus followed by 2 micrograms/kg/min)
Study: 30667502
Drug: Low free
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low free sugar diet (restricted to less than 3% of daily calories for 8 weeks)
Study: 27640607
Drug: naproxen plus
Normalized name: Naproxen
DrugBank: Naproxen (DB00788)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: naproxen plus oxycodone/acetaminophen
Study: 24528604
Drug: Assertive Community
Approvals — FDA: no, EMA: no, PMDA: no
Description: Assertive Community Treatment (ACT) for elderly patients
Study: 22920800
Drug: Rapid-acting insulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rapid-acting insulin + recombinant human hyaluronidase (rHuPH20)
Study: 22920800
Drug: Continuous subcutaneous
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous subcutaneous infusion of rapid-acting insulin + rHuPH20
Study: 22920800
Drug: Subcutaneous injection
Normalized name: EPINEPHRINE 0.3 mg SUBCUTANEOUS INJECTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous injection of rapid-acting insulin + rHuPH20
Study: 21056840
Drug: Electro-acupuncture and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Electro-acupuncture and behavior therapy
Study: 21056840
Drug: Sham electro-acupuncture
Normalized name: ELECTRODE SPRAY,ELECTRO MIST
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham electro-acupuncture and behavior therapy
Study: 10535857
Drug: Vitamin C
Normalized name: Vitamin C
DrugBank: Sodium ascorbate (DB14482)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin C 500 mg + Vitamin E 100 mg twice daily
Study: 8584522
Drug: 0.2 mg
Normalized name: niacin 0.2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.2 mg Fenoterol
Study: 8584522
Drug: 0.2 mg
Normalized name: niacin 0.2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.2 mg Salbutamol
Study: 8584522
Drug: 0.05 mg
Normalized name: biotin 0.05 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.05 mg Salmeterol
Study: 8584522
Drug: Rescue medication
Normalized name: ALLERGENIC EXTRACT, MEADOW FESCUE POLLEN
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rescue medication (Salbutamol MDI)
Study: 2338888
Drug: Naloxone (1.6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naloxone (1.6 mg/h for 4 h)
Study: 27960614
Drug: Long-term individual
Normalized name: benzethonium
DrugBank: Benzethonium (DB11125)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Long-term individual shear rate therapy (ISRT)
Study: 26578736
Drug: Medroxyprogesterone acetate
Normalized name: Medroxyprogesterone Acetate
DrugBank: Medroxyprogesterone acetate (DB00603)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Medroxyprogesterone acetate (MPA) 400 mg/day plus metformin 750-2250 mg/day for 24-36 weeks
Study: 24948402
Drug: memantine (maximal
Approvals — FDA: no, EMA: no, PMDA: no
Description: memantine (maximal dose 20 mg/day)
Study: 24948402
Drug: dextromethorphan (maximal
Approvals — FDA: no, EMA: no, PMDA: no
Description: dextromethorphan (maximal dose 90 mg/day)
Study: 19934286
Drug: CH4987655 (0.5,
Approvals — FDA: no, EMA: no, PMDA: no
Description: CH4987655 (0.5, 1, 2, 3, and 4 mg)
Study: 18062141
Drug: Gardasil vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gardasil vaccine
Study: 11437394
Drug: High-dose IM
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose IM Medroxyprogesterone acetate (HD-MPA) adjuvant hormonotherapy during 6 months
Study: 9544333
Drug: 0.9% sodium
Normalized name: LMD with 0.9% Sodium Chloride
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.9% sodium chloride injection with heparin sodium 10 units/mL
Study: 9544333
Drug: 0.9% sodium
Normalized name: LMD with 0.9% Sodium Chloride
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.9% sodium chloride injection without heparin sodium
Study: 29518178
Drug: Delafloxacin 300
Normalized name: delafloxacin 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Delafloxacin 300 mg IV every 12 hours for 3 days followed by 450 mg oral delafloxacin
Study: 29518178
Drug: Vancomycin 15
Normalized name: vancomycin 1500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vancomycin 15 mg/kg IV with aztreonam for 5-14 days
Study: 23749688
Drug: 8-week supervised
Normalized name: lacosamide
DrugBank: Lacosamide (DB06218)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 8-week supervised aerobic exercise training (twice weekly)
Study: 16862472
Drug: Single dose
Normalized name: Citrucel Single Dose Packets (Orange)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose of intravenous cephalothin 2 g, intraoperatively
Study: 16862472
Drug: Standard antibiotics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard antibiotics scheme followed at this center (penicillin)
Study: 9009151
Drug: Nicotine patch
Normalized name: Nicotine Patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nicotine patch therapy (group Q)
Study: 9009151
Drug: Nicotine patch
Normalized name: Nicotine Patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nicotine patch therapy (group R)
Study: 12518122
Drug: Placebo patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo patch (control group)
Study: 30580198
Drug: Anxiolytics
Normalized name: ANXIOLYTICS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anxiolytics
Study: 30445895
Drug: Higher antipsychotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Higher antipsychotic dosage at discharge
Study: 20347286
Drug: Traditional exercise
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Traditional exercise therapy (TET) program
Study: 10342080
Drug: Methotrexate alone
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Methotrexate alone (50 mg/m2 intramuscularly)
Study: 8620703
Drug: Oral prednisolone,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral prednisolone, 50 mg (PRED)
Study: 8620703
Drug: Inhaled fluticasone
Normalized name: fluticasone Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled fluticasone propionate, 1,000 micrograms (F1000)
Study: 8620703
Drug: Inhaled fluticasone
Normalized name: fluticasone Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled fluticasone propionate, 2,000 micrograms (F2000)
Study: 1835830
Drug: Dilute heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dilute heparin solution
Study: 7343723
Drug: guanethidine/epinephrine combination
Approvals — FDA: no, EMA: no, PMDA: no
Description: guanethidine/epinephrine combination
Study: 23426616
Drug: L-carnitine supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-carnitine supplementation (100 mg/kg/d for 4 weeks)
Study: 19276620
Drug: both supplements
Normalized name: Bothrops atrox venom
Approvals — FDA: no, EMA: no, PMDA: no
Description: both supplements (antioxidants and n-3 fatty acids)
Study: 11782332
Drug: Epidural sufentanil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural sufentanil with epinephrine (100 microg/mL)
Study: 7703623
Drug: MFP-calcium-treated group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: MFP-calcium-treated group (sodium monofluorophosphate 26 mg/day of fluoride + 1000 mg of calcium)
Study: 1064725
Drug: Oxygel application
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxygel application and tooth brushing twice a day
Study: 31392401
Drug: 28.2-μg twice-weekly
Approvals — FDA: no, EMA: no, PMDA: no
Description: 28.2-μg twice-weekly teriparatide
Study: 31392401
Drug: 56.5-μg once-weekly
Approvals — FDA: no, EMA: no, PMDA: no
Description: 56.5-μg once-weekly teriparatide
Study: 25482330
Drug: Simeprevir (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simeprevir (150 mg once a day) plus peginterferon alfa‐2a and ribavirin
Study: 25482330
Drug: Telaprevir (750
Approvals — FDA: no, EMA: no, PMDA: no
Description: Telaprevir (750 mg three times a day) plus peginterferon alfa‐2a and ribavirin
Study: 20137594
Drug: Xue Bijing
Normalized name: Ji Xue Cao Whole
DrugBank: Centella asiatica (DB14256)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Xue Bijing injection, 100 ml intravenous once a day for 7 days
Study: 20137594
Drug: Xue Bijing
Normalized name: Ji Xue Cao Whole
DrugBank: Centella asiatica (DB14256)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Xue Bijing injection
Study: 15228371
Drug: Preferred biologic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preferred biologic therapy recommended for prior-authorization (PA) criteria
Study: 15228371
Drug: Biologic agent
Normalized name: Cytokine-based biologic agent IRX-2
DrugBank: IRX-2 (DB05643)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Biologic agent with marginal incremental clinical benefit
Study: 15228371
Drug: Biologic agent
Normalized name: Cytokine-based biologic agent IRX-2
DrugBank: IRX-2 (DB05643)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Biologic agent with increased efficacy
Study: 15228371
Drug: Flexible PA
Normalized name: LIDOCAINE 40 mg in 1 g TOPICAL PATCH [Walgreens Flexible Pain Relieving Lidocaine]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flexible PA criteria for drug coverage
Study: 11703235
Drug: Intraperitoneal bupivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intraperitoneal bupivacaine with Hartmann's solution
Study: 11703235
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (Hartmann's solution without bupivacaine)
Study: 9130221
Drug: 3% mepivicaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3% mepivicaine (1.0 ml)
Study: 8190448
Drug: Ampicillin-sulbactam (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ampicillin-sulbactam (3 g every 6 hours)
Study: 8190448
Drug: Cefoxitin (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefoxitin (2 g every 6 hours) plus doxycycline (100 mg every 12 hours)
Study: 8190448
Drug: Clindamycin (900
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clindamycin (900 mg every 8 hours) plus gentamicin (1.5 mg/kg every 8 hours)
Study: 3370078
Drug: Piracetam 2400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Piracetam 2400 mg
Study: 30460634
Drug: 5-Azacytidine (5-AZA)
DrugBank: Azacitidine (DB00928)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 5-Azacytidine (5-AZA) 10 mg infusions, 12 consecutive weekly infusions planned
Study: 27858681
Drug: Osteopathic manual
Approvals — FDA: no, EMA: no, PMDA: no
Description: Osteopathic manual therapy (OMT) and exercise methods
Study: 27858681
Drug: Visceral osteopathic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Visceral osteopathic manual therapy (vOMT)
Study: 17909808
Drug: 250 mg
Normalized name: rutin 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 250 mg granular formulation of gefitinib
Study: 17909808
Drug: 250 mg
Normalized name: rutin 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 250 mg tablet of gefitinib
Study: 10918945
Drug: Calcium antagonist
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium antagonist (benidipine)
Study: 10918945
Drug: Angiotensin converting
Normalized name: Angiotensin converting enzyme
Approvals — FDA: no, EMA: no, PMDA: no
Description: Angiotensin converting enzyme inhibitor (trandolapril)
Study: 6139191
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of hydroxyzine (10 mg qds) and cimetidine (400 mg qds)
Study: 6139191
Drug: Other antihistamine
Normalized name: Other antihistamines for systemic use
Approvals — FDA: no, EMA: no, PMDA: no
Description: Other antihistamine regimes
Study: 22406278
Drug: ProQuad(®) (MMRV
Approvals — FDA: no, EMA: no, PMDA: no
Description: ProQuad(®) (MMRV vaccine) Dose 1 at 9 months
Study: 22406278
Drug: ProQuad(®) (MMRV
Approvals — FDA: no, EMA: no, PMDA: no
Description: ProQuad(®) (MMRV vaccine) Dose 1 at 11 months
Study: 22406278
Drug: ProQuad(®) (MMRV
Approvals — FDA: no, EMA: no, PMDA: no
Description: ProQuad(®) (MMRV vaccine) Dose 1 at 12 months
Study: 22406278
Drug: ProQuad(®) (MMRV
Approvals — FDA: no, EMA: no, PMDA: no
Description: ProQuad(®) (MMRV vaccine) Dose 1 at 9 months, 11 months, or 12 months
Study: 17916667
Drug: 6% glucose
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6% glucose beverage (1.00 g carbohydrate/kg body mass)
Study: 3629428
Drug: Sputum cytologic
Normalized name: human sputum, Bordetella pertussis infected
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sputum cytologic examinations (4-monthly)
Study: 25976690
Drug: Arthrocentesis plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Arthrocentesis plus platelet-rich plasma (PRP) injection and then 4 consecutive PRP injections
Study: 9834207
Drug: G-CSF treatment
Normalized name: G-CSF
DrugBank: Lenograstim (DB13144)
Approvals — FDA: no, EMA: no, PMDA: no
Description: G-CSF treatment
Study: 16556754
Drug: Extracorporeal shockwave
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Extracorporeal shockwave treatment (1500 impulses at 16 kV in a single session)
Study: 14505915
Drug: Intranasal virosome
Normalized name: influenza A virus (H1N1) antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal virosome vaccine adjuvanted with heat-labile toxin (HLT)
Study: 14505915
Drug: Intranasal vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal vaccine without HLT
Study: 8738052
Drug: Casodex 50
Normalized name: Casodex 50mg Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Casodex 50 mg monotherapy
Study: 1582291
Drug: Astemizole (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Astemizole (10 mg/ml)
Study: 29249532
Drug: n-3 PUFA
Normalized name: 22:6(n-3)
Approvals — FDA: no, EMA: no, PMDA: no
Description: n-3 PUFA (0.945 g/day, 64% ALA, 21% EPA, 16% DHA)
Study: 22935844
Drug: 1 g
Normalized name: Molds 1 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 g of intravenous L-carnitine after each dialysis session for 1 year
Study: 12662379
Drug: N-acetyl cystein
Normalized name: N-Acetyl Cysteine
Approvals — FDA: no, EMA: no, PMDA: no
Description: N-acetyl cystein (4%) 5 ml t.i.d. for 3 days (AC group, n = 53)
Study: 9830877
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of social support and education
Study: 2869573
Drug: Beta‐2 agonist
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beta‐2 agonist terbutaline (0.50 mg)
Study: 2869573
Drug: Beta‐1 agonist
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beta‐1 agonist prenalterol (less than or equal to 5 mg)
Study: 22365802
Drug: Acute low
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acute low dose tryptophan depletion (ATD)
Study: 20569146
Drug: Oral PrEP
Normalized name: Iron bivalent, oral preparations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral PrEP for HIV prevention
Study: 8602477
Drug: Intervention group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intervention group (treatment for subacute low back pain)
Study: 1974628
Drug: Ribavirin 800
Normalized name: ribavirin 800 Dose Pack, 4 Unit Dose Packs, 14 Tablets Each
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ribavirin 800 mg
Study: 1974628
Drug: Ribavirin 600
Normalized name: ribavirin 600 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ribavirin 600 mg
Study: 22958738
Drug: Standard CNI-therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard CNI-therapy
Study: 19203529
Drug: Hutex omeprazole
Normalized name: Omeprazole
DrugBank: Omeprazole (DB00338)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hutex omeprazole (20 mg)
Study: 19203529
Drug: Yuhan Losec
Normalized name: Losec
DrugBank: Omeprazole (DB00338)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Yuhan Losec (20 mg)
Study: 17970234
Drug: Intravenous rasburicase
Normalized name: Rasburicase
DrugBank: Rasburicase (DB00049)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Intravenous rasburicase at a dose of 0.02 mg/kg/day for varying durations based on serum uric acid levels (3 days for 8-10 mg/dl, 5 days for 10-15 mg/dl, 7 days for >15 mg/dl)
Study: 7774443
Drug: Combined operative
Normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Combined operative resection and immuno-chemotherapy (OIC)
Study: 7774443
Drug: Combined operative
Normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Combined operative resection and immunotherapy (OI)
Study: 7774443
Drug: Combined operative
Normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Combined operative resection and chemotherapy (OC)
Study: 2328258
Drug: L-carnitine (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-carnitine (2 g)
Study: 20872758
Drug: Readiness and
Normalized name: norgestimate and ethinylestradiol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Readiness and Motivation Therapy (RMT)
Study: 19576320
Drug: Triple antiplatelet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triple antiplatelet regimen (aspirin plus clopidogrel plus cilostazol)
Study: 19576320
Drug: Dual antiplatelet
Normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dual antiplatelet regimen (aspirin plus clopidogrel)
Study: 15374367
Drug: Idebenone 45
Normalized name: idebenone 45 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Idebenone 45 mg twice daily p.o.
Study: 15374367
Drug: Oxiracetam 800
Normalized name: oxiracetam 800 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxiracetam 800 mg twice daily p.o.
Study: 31778196
Drug: Single-dose antibiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-dose antibiotic therapy
Study: 30134944
Drug: Surgical treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Surgical treatment with posterior C1-C2 fusion
Study: 30134944
Drug: Non-surgical treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-surgical treatment with a rigid cervical collar for 12 weeks
Study: 26970335
Drug: 2.6 g
Normalized name: SODIUM BICARBONATE 2.6 g in 2.6 g ORAL POWDER
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.6 g omega‐3 LCPUFA supplementation
Study: 26970335
Drug: Placebo of
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo of 2.7 g soya bean oil
Study: 21693549
Drug: Pregabalin 300-600
Normalized name: pregabalin 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pregabalin 300-600 mg/day
Study: 15781528
Drug: IV fluid
Normalized name: IV fluid
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV fluid administration
Study: 15781528
Drug: Fluid types
Normalized name: amniotic fluid (bovine)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluid types and administration strategies
Study: 10682127
Drug: Zalcitabine 0.75
Normalized name: zalcitabine 0.75 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zalcitabine 0.75 mg every 8 hours
Study: 10682127
Drug: Saquinavir 600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saquinavir 600 mg every 8 hours
Study: 10682127
Drug: Combination zalcitabine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination zalcitabine 0.75 mg plus saquinavir 600 mg every 8 hours
Study: 1747216
Drug: Quinapril (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quinapril (5 mg oral twice daily, titrated to 20 mg twice daily)
Study: 1747216
Drug: Captopril (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Captopril (25 mg oral twice daily, titrated to 100 mg twice daily)
Study: 402697
Drug: b.i.d. dosage
Approvals — FDA: no, EMA: no, PMDA: no
Description: b.i.d. dosage schedule of 500 mg twice daily
Study: 402697
Drug: t.i.d. dosage
Approvals — FDA: no, EMA: no, PMDA: no
Description: t.i.d. dosage schedule of 250 mg three times daily
Study: 31708422
Drug: Ketamine (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketamine (0.5 mg/kg bolus before incision, followed by 0.5 mg/kg/h infusion until end of surgery)
Study: 28671307
Drug: Insulin iontophoresis
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Insulin iontophoresis in IS groups (ABIS and SCIS)
Study: 28671307
Drug: Net insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Net insulin response (NetIns) in IS cohorts (ABIS and SCIS)
Study: 23439596
Drug: L‐NMMA (NOS
Approvals — FDA: no, EMA: no, PMDA: no
Description: L‐NMMA (NOS inhibitor)
Study: 15987284
Drug: Tacalcitol ointment
Normalized name: tacalcitol
DrugBank: Tacalcitol (DB13689)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tacalcitol ointment (4 microg/g) applied once daily for 2 months
Study: 12962951
Drug: Tolterodine extended
Normalized name: tolterodine Extended Release Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tolterodine extended release 4 mg once daily
Study: 10543293
Drug: Home i.v.
Approvals — FDA: no, EMA: no, PMDA: no
Description: Home i.v. antibiotic treatment (HIVAT, 14 days)
Study: 10543293
Drug: Inhaled amiloride
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled amiloride (14 days)
Study: 713434
Drug: Tinofedrine (0.12‐‐0.17
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tinofedrine (0.12‐‐0.17 mg/kg bodyweight)
Study: 24287284
Drug: 1.8 g/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.8 g/day esterified plant sterols and stanols
Study: 20350253
Drug: Xuezhikang (0.6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Xuezhikang (0.6 g twice daily)
Study: 15986863
Drug: Partially hydrolyzed
Normalized name: Human Skin Proteins, Partially Hydrolyzed
Approvals — FDA: no, EMA: no, PMDA: no
Description: Partially hydrolyzed guar gum (PHGG) 5 g/day
Study: 12184518
Drug: Wheat bran
Normalized name: Wheat bran
DrugBank: Wheat bran (DB10685)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Wheat bran 30 g/day
Study: 15361500
Drug: CDP571 (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: CDP571 (10 mg/kg)
Study: 7788147
Drug: CDP571 (1.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: CDP571 (1.0 mg/kg)
Study: 7788147
Drug: CDP571 (0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: CDP571 (0.1 mg/kg)